The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REGOSTA: A randomized, placebo-controlled, double-blinded, multicenter study evaluating the efficacy and safety of regorafenib (REGO) as maintenance therapy after first-line treatment in patients (pts) with osteosarcoma (OS) and non-osteosarcomas (non-OS) of bone (non-Ewing, non-chondrosarcomas and non-chordomas).
 
Florence Duffaud
Consulting or Advisory Role - Bayer Health
Travel, Accommodations, Expenses - Leo Pharma; PharmaMar
 
Sylvie Chabaud
No Relationships to Disclose
 
Julien Gautier
No Relationships to Disclose
 
Celine Ferlay
No Relationships to Disclose
 
Séraphine Vizoso
No Relationships to Disclose
 
Mehdi Brahmi
Expert Testimony - Bayer
Travel, Accommodations, Expenses - mundipharma; PharmaMar
 
Sarah Benezech
No Relationships to Disclose
 
Armelle Dufresne
No Relationships to Disclose
 
Perrine Marec-Berard
No Relationships to Disclose
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; DECIPHERA; Genmab; GlaxoSmithKline; MERSANA; MSD Oncology; OxOnc; Pfizer; PharmaMar; Roche; Tesaro
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Deciphera; Genmab; GlaxoSmithKline; Mersana; Mersana; MSD Oncology; Pfizer; PharmaMar; Roche; Tesaro
Research Funding - BMS; MSD Oncology
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; French National Cancer Institute (INCA)
 
Elsa Kalbacher
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline/Tesaro
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline/Novartis; LEO Pharma; Sanofi; Tesaro
 
Olivier Collard
No Relationships to Disclose
 
Nicolas Penel
Research Funding - Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Janssen-Cilag
Other Relationship - PharmaMar
 
Maria Rios
No Relationships to Disclose
 
Emmanuelle Bompas
No Relationships to Disclose
 
Christine Chevreau
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer/Ipsen
 
Olivier Mir
Stock and Other Ownership Interests - Amplitude Surgical; Ipsen; Transgene
Honoraria - Roche
Consulting or Advisory Role - Janssen; Lilly; Lundbeck; Pfizer; Roche
Speakers' Bureau - Lilly; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Ipsen
Travel, Accommodations, Expenses - Pfizer; Roche
 
Pascaline Boudou-Rouquette
No Relationships to Disclose
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Sophie Piperno-Neumann
Consulting or Advisory Role - Immunocore
Research Funding - MSD (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis; PharmaMar